Aquestive Therapeutics, Inc. AQST Business Segments — Total Selling expenses

Similar metrics at other companies

SUPNReportable Segment — Selling expenses

$66.28M+55.5%

MATWReportable Segments Total — Selling Expense

$25.89M-29.2%

ARDXReportable Segment — Selling

$67.4M+18.7%

KRT

KRTReportable Segment — Selling expenses

$1.54M-30.6%

PEGAReportable Segment — Selling

$133.14M+11.8%

GILDReportable Segment — Selling and marketing expenses

$898M+19.3%

Questions, answered.

What is Aquestive Therapeutics, Inc.'s business segments — total selling expenses?

Aquestive Therapeutics, Inc. (AQST) reported business segments — total selling expenses of $1.92M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s business segments — total selling expenses changed year-over-year?

Aquestive Therapeutics, Inc.'s business segments — total selling expenses decreased by 35.0% year-over-year, from $2.96M to $1.92M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — total selling expenses?

Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — total selling expenses has grown at a 235.8% compound annual growth rate (CAGR), from $1.64M to $18.48M.

What does business segments — total selling expenses mean?

Encompasses all costs related to the marketing, promotion, and sales force activities required to drive product adoption within the segment. This metric measures the investment intensity required to compete in the pharmaceutical market and acquire or retain customers. High levels of these expenses are often associated with new product launches or aggressive market expansion.